Report Description Table of Contents How Are Genetic Screening, Implantable Defibrillators, and Emerging Gene Therapies Reshaping the Arrhythmogenic Right Ventricular Dysplasia Market? The Global Arrhythmogenic Right Ventricular Dysplasia (ARVD) Market was valued at USD 1.05 billion in 2025 and is projected to reach USD 1.62 billion by 2032, expanding at a CAGR of 6.4% during 2026–2032, according to Strategic Market Research. ARVD, also known as Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), is an inherited heart condition with an estimated prevalence of 1 in 1,000–2,000 people. Symptoms typically emerge between ages 10 and 50, while approximately 30–50% of patients have a recognized family history, creating opportunities for genetic testing, family screening, and long-term cardiac monitoring. ARVD is associated with an elevated risk of sudden cardiac death, particularly among younger individuals and competitive athletes. Studies have attributed approximately 11–22% of sudden cardiac deaths in certain young-athlete populations to the condition, although estimates vary across studies. Genetic screening, electrocardiography, cardiac MRI, and ambulatory rhythm monitoring support earlier identification and ongoing clinical assessment. In families affected by autosomal dominant ARVD, each child may have a 50% chance of inheriting the disease-associated genetic variant, supporting continued use of genetic counseling and targeted family screening. Implantable cardioverter-defibrillators (ICDs), antiarrhythmic medications, and catheter ablation represent important treatment-related opportunities. ICDs are central to preventing sudden cardiac death in eligible high-risk patients, while beta-blockers, other antiarrhythmic drugs, and heart failure therapies contribute to ongoing disease management. Catheter ablation addresses recurrent ventricular arrhythmias, with heart transplantation reserved for selected advanced cases. Emerging gene therapies offer longer-term research opportunities, although they remain investigational. For market participants, expanding genetic diagnosis, specialized electrophysiology services, device implantation, and lifelong cardiac monitoring represent important areas of commercial activity. Market Segment Analysis: Which ARVD Treatments, Diagnostic Technologies, and Healthcare Settings Lead Revenue and Growth? By Treatment Type: ICDs Anchor Care as Catheter Ablation Gains Momentum Largest Subsegment – Implantable Cardioverter Defibrillators (ICDs) Implantable cardioverter-defibrillators (ICDs) remain the leading life-saving intervention for preventing sudden cardiac death in patients with Arrhythmogenic Right Ventricular Dysplasia (ARVD/C), particularly those experiencing sustained ventricular arrhythmias or facing elevated cardiac risk. ICDs accounted for an estimated 42% of the global Arrhythmogenic Right Ventricular Dysplasia Market, valued at USD 441 million in 2025, and are projected to expand at a 6.7% CAGR during 2026–2032. Increasing identification of high-risk patients and wider adoption of preventive ICD implantation continue to support treatment utilization globally. Fastest-Growing Subsegment – Catheter Ablation Catheter ablation accounted for approximately 19% of the global Arrhythmogenic Right Ventricular Dysplasia (ARVD) Market in 2025, representing a market value of USD 200 million, and is projected to expand at a CAGR of 8.9% during 2026–2032. It serves as an effective secondary intervention for reducing recurrent, drug-refractory ventricular tachycardia in patients with Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC). Increasing use of catheter ablation to manage persistent ventricular arrhythmias and reduce implantable cardioverter-defibrillator shocks is supporting its growing clinical adoption. By Drug Class: Beta-Blockers Lead as Supportive Therapy Needs Expand Largest Subsegment – Beta-Blockers Beta-blockers remain a first-line medical therapy in the Arrhythmogenic Right Ventricular Dysplasia (ARVD) Market, helping control abnormal heart rhythms by blocking adrenaline and reducing sympathetic stimulation of the heart. In 2025, beta-blockers accounted for an estimated 38% share of the drug-class allocation, equivalent to USD 399 million, and are projected to grow at a 5.6% CAGR during 2026–2032. Their established role in managing ventricular arrhythmias, reducing adrenergic triggers, and supporting long-term cardiac care reinforces their importance in ARVD treatment. Fastest-Growing Subsegment – Other Supportive Medications Other supportive medications accounted for an estimated 5% share of the global Arrhythmogenic Right Ventricular Dysplasia Market in 2025, equivalent to USD 53 million, and are projected to grow at a CAGR of 7.8% during 2026–2032. Medications such as diuretics, ACE inhibitors, and beta-blockers help manage heart failure symptoms, reduce cardiac workload, and control abnormal heart rhythms in patients with arrhythmogenic right ventricular cardiomyopathy (ARVD/C). Their clinical importance is increasing as disease progression requires long-term symptom management alongside implantable defibrillators and other cardiac interventions. By Diagnostic Method: ECG Leads Today as Genetic Testing Accelerates Largest Subsegment – Electrocardiography (ECG) Electrocardiography (ECG) accounted for approximately 25% of the modeled diagnostic allocation in the Arrhythmogenic Right Ventricular Dysplasia (ARVD/C) Market, valued at USD 263 million in 2025, and is projected to expand at a 5.4% CAGR during 2026–2032. As a widely used non-invasive diagnostic method, ECG helps identify electrical abnormalities associated with fibrofatty myocardial replacement, including T-wave inversions, epsilon waves, and ventricular conduction disturbances. Its role in early cardiac assessment, arrhythmia identification, and ongoing patient monitoring supports continued clinical utilization across cardiology facilities. Fastest-Growing Subsegment – Genetic Testing Genetic testing plays a central role in the Arrhythmogenic Right Ventricular Dysplasia Market by confirming inherited disease-associated variants, identifying at-risk family members, and clarifying borderline clinical diagnoses. It accounted for an estimated 20% market share in 2025, equivalent to USD 210 million, and is projected to grow at a 10.8% CAGR during 2026–2032. Increasing use of family screening, cascade genetic testing, and early identification of pathogenic variants is expanding testing opportunities, particularly among relatives of diagnosed ARVD/C patients requiring long-term cardiac surveillance. By Device Type: Transvenous ICDs Lead as Subcutaneous Systems Advance Largest Subsegment – Transvenous Implantable Cardioverter Defibrillators Transvenous Implantable Cardioverter Defibrillators (ICDs) accounted for an estimated 53% share of the modeled device allocation in the Arrhythmogenic Right Ventricular Dysplasia (ARVD/C) Market, representing USD 557 million in 2025, with a projected 5.8% CAGR during 2026–2032. Transvenous ICDs remain an established life-saving treatment for ARVD/C patients at high risk of sudden cardiac death. Their ability to detect and terminate life-threatening ventricular arrhythmias, combined with established clinical use in high-risk patients, supports their continued prominence in ARVD/C cardiac device treatment. Fastest-Growing Subsegment – Subcutaneous Implantable Cardioverter Defibrillators Subcutaneous Implantable Cardioverter Defibrillators (S-ICDs) accounted for an estimated 21% of the Arrhythmogenic Right Ventricular Dysplasia Market in 2025, valued at USD 221 million, and are projected to expand at a 10.5% CAGR during 2026–2032. S-ICDs provide an effective alternative to traditional transvenous defibrillators for preventing sudden cardiac death in patients with Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy (ARVD/C). Their non-transvenous design avoids intravascular leads, reducing lead-related complications and making them particularly relevant for younger patients requiring long-term protection against life-threatening ventricular arrhythmias. By End User: Hospitals Lead Care as Diagnostic Centers Expand Faster Largest Subsegment – Hospitals Hospitals accounted for an estimated 62% share of the global Arrhythmogenic Right Ventricular Dysplasia Market in 2025, representing USD 651 million, and are projected to grow at a 5.9% CAGR during 2026–2032. Hospitals serve as primary centers for diagnosing and managing ARVD, a potentially fatal inherited heart disorder associated with abnormal replacement of heart muscle by fatty and fibrous tissue. Specialized cardiac imaging, genetic testing, electrophysiology services, implantable defibrillator procedures, and long-term arrhythmia monitoring reinforce their leading market position. Fastest-Growing Subsegment – Diagnostic Centers Diagnostic centers accounted for approximately 13% of the global Arrhythmogenic Right Ventricular Dysplasia Market in 2025, valued at USD 137 million, and are projected to grow at a CAGR of 9.3% during 2026–2032. Specialized diagnostic facilities play an essential role in identifying ARVD/C through cardiac MRI, electrocardiography, genetic testing, and multidisciplinary cardiac evaluations. Growing recognition of inherited cardiac disorders, increased genetic screening among high-risk families, and earlier identification of arrhythmogenic conditions are supporting greater utilization of specialized diagnostic services worldwide. By Geography: North America Leads as Asia-Pacific Builds Momentum Largest Region – North America North America dominated the Arrhythmogenic Right Ventricular Dysplasia (ARVD) Market, accounting for an estimated 41% of the global market, valued at USD 431 million in 2025, with a projected CAGR of 5.8% during 2026–2032. ARVD, increasingly referred to as Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), is a rare inherited heart disorder associated with potentially life-threatening arrhythmias. Established cardiac electrophysiology centers, wider availability of genetic testing, and greater use of implantable cardioverter-defibrillators support diagnosis, clinical management, and treatment expenditure across the United States and Canada. Fastest-Growing Region – Asia-Pacific Asia-Pacific accounted for approximately 19% of the global Arrhythmogenic Right Ventricular Dysplasia Market in 2025, representing a market value of USD 200 million, and is projected to register the fastest regional CAGR of 9.2% during 2026–2032. Clinical diagnosis across the region relies heavily on international diagnostic guidelines adapted to local genetic variations. Expanding cardiovascular screening, improved genetic testing access, and growing recognition of inherited arrhythmogenic disorders in China, Japan, India, and South Korea are expected to accelerate diagnosis and treatment adoption. Competitive Landscape: How Are Leading Cardiac Device Manufacturers and Genetic Testing Companies Advancing the ARVD Market? Medtronic: Extravascular Defibrillator Innovation Expands Cardiac Protection Technologies Medtronic is a major participant in implantable cardiac rhythm management, offering technologies relevant to the prevention of sudden cardiac death in high-risk ARVC patients. Its Aurora EV-ICD system, approved by the FDA in 2023, delivers defibrillation and antitachycardia pacing through a lead positioned outside the heart and veins. Clinical evidence reported by Medtronic demonstrated a 98.7% successful defibrillation rate during implantation. In its real-world ENLIGHTEN study, the company reported 97.8% freedom from system-related major complications at six months and 100% shock success for discrete spontaneous arrhythmia episodes. The technology offers an additional device option for appropriately selected ARVC patients, although the study outcomes represent broader ICD populations rather than ARVC-specific results. BIOTRONIK: Single-Lead ICD Technology Strengthens Long-Term Arrhythmia Monitoring BIOTRONIK competes through implantable defibrillators, cardiac monitoring systems, and remote patient management technologies. Its proprietary DX Technology combines ventricular defibrillation with direct atrial sensing through a single-lead system, allowing clinicians to identify atrial arrhythmias without an additional atrial lead. In January 2024, BIOTRONIK announced that its DX technology had surpassed 100,000 device implantations across more than 80 countries. Its clinical evidence program includes over 20 studies involving more than 4,000 patients. In April 2026, the company also announced FDA approval for its Acticor Sky and Rivacor Sky device families, expanding its cardiac rhythm management portfolio. These developments strengthen its position in long-term rhythm monitoring and defibrillator technologies relevant to inherited cardiomyopathies. Other Companies Supporting ARVD Diagnostics and Treatment Development: Tenaya Therapeutics: Developing TN-401, an investigational gene therapy targeting PKP2-associated ARVC, which received FDA Regenerative Medicine Advanced Therapy designation in September 2026. CENTOGENE: Provides molecular genetic testing and rare disease diagnostic services applicable to inherited cardiomyopathies. Ambry Genetics: Offers hereditary cardiovascular genetic testing to identify pathogenic variants associated with inherited arrhythmias and cardiomyopathies. GeneDx: Provides genomic sequencing and genetic interpretation services relevant to diagnosing inherited cardiac disorders. Illumina: Supplies next-generation sequencing platforms used by clinical laboratories for identifying genetic variants associated with hereditary cardiac diseases. Blueprint Genetics: Provides inherited cardiac disease testing panels covering cardiomyopathy-associated genes and hereditary arrhythmia conditions. Labcorp (Invitae): Provides hereditary genetic testing capabilities following its August 2024 acquisition of select Invitae assets, expanding access to specialty genetic diagnostics. Analyst Commentary: How Will Genetic Diagnosis and Device Innovation Shape the Next Phase of ARVD Care? The Arrhythmogenic Right Ventricular Dysplasia Market presents a specialized growth opportunity driven by earlier genetic diagnosis, preventive cardiac care, and increasing use of implantable defibrillators in high-risk patients. The strongest commercial opportunities lie in hereditary genetic screening, advanced cardiac MRI, long-term arrhythmia monitoring, and minimally invasive catheter ablation. Emerging gene therapies targeting inherited mutations could reshape the treatment landscape by addressing underlying disease mechanisms. However, limited patient populations, high treatment costs, and uneven access to specialized cardiac care remain important barriers to wider market expansion. Arrhythmogenic Right Ventricular Dysplasia Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 1.05 Billion Revenue Forecast in 2032 USD 1.62 Billion Overall Growth Rate CAGR of 6.4% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Treatment Type, By Drug Class, By Diagnostic Method, By Device Type, By End User, By Geography By Treatment Type Implantable Cardioverter Defibrillators (ICDs), Medication, Catheter Ablation, Heart Transplantation By Drug Class Beta-Blockers, Antiarrhythmic Drugs, ACE Inhibitors and ARBs, Diuretics, Other Supportive Medications By Diagnostic Method Electrocardiography (ECG), Cardiac Magnetic Resonance Imaging (MRI), Genetic Testing, Echocardiography, Holter and Ambulatory ECG Monitoring, Electrophysiological Studies By Device Type Transvenous Implantable Cardioverter Defibrillators, Subcutaneous Implantable Cardioverter Defibrillators, Cardiac Monitoring Devices By End User Hospitals, Specialty Cardiology Clinics, Diagnostic Centers, Ambulatory Surgical Centers By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Increasing genetic screening and family-based diagnosis, rising risk of sudden cardiac death, greater adoption of implantable cardioverter-defibrillators, growing use of catheter ablation for recurrent ventricular arrhythmias, expansion of cardiac MRI and ambulatory rhythm monitoring, improving access to electrophysiology services, and development of emerging gene therapies for inherited ARVD/ARVC Customization Option Available upon request Frequently Asked Question About This Report Q1: What are the main factors driving growth in the market? A1: Growth is being supported by earlier genetic diagnosis, wider family screening, increasing use of implantable defibrillators, and greater access to specialized electrophysiology services. Q2: What are the key trends shaping the industry? A2: The industry is moving toward genetic risk assessment, advanced cardiac MRI, long-term rhythm monitoring, minimally invasive catheter ablation, and newer defibrillator designs that reduce lead-related complications. Q3: Why is genetic testing becoming more important in the market? A3: Genetic testing helps identify inherited disease variants and at-risk relatives before severe symptoms develop. Its role is expanding as cascade screening and lifelong monitoring become more common in affected families. Q4: How are implantable defibrillators influencing the industry? A4: Implantable defibrillators remain central to preventing sudden cardiac death in high-risk patients. Newer subcutaneous and extravascular designs are also creating alternatives that can reduce complications associated with traditional transvenous leads. Q5: Which treatment approach is showing the fastest growth in the market? A5: Catheter ablation is projected to be the fastest-growing treatment category, with an estimated CAGR of 8.9% during 2026–2032. It is increasingly used to manage recurrent ventricular arrhythmias and reduce repeated ICD shocks. Q6: Why are diagnostic centers gaining importance in the industry? A6: Diagnostic centers are expanding their role through cardiac MRI, ECG, genetic testing, and ambulatory rhythm monitoring. Greater recognition of inherited cardiac disorders is increasing demand for specialized diagnostic evaluation. Q7: What emerging technologies could reshape the market? A7: Gene therapies targeting inherited mutations could become an important long-term development area. Advanced cardiac imaging, remote monitoring, next-generation sequencing, and newer defibrillator technologies are also expected to influence future care. Q8: Which region is expected to record the fastest growth in the industry? A8: Asia-Pacific is projected to record the fastest regional CAGR of about 9.2% during 2026–2032. Growth is supported by improving cardiovascular screening, wider genetic testing access, and greater recognition of inherited arrhythmogenic disorders. Sources: NIH/NCBI GeneReviews – ARVC Prevalence, Genetics, Family Screening, ICD Treatment and Sudden Cardiac Death Risk NCBI GeneReviews – Arrhythmogenic Right Ventricular Cardiomyopathy Overview Heart Rhythm Society – ARVC/Arrhythmogenic Cardiomyopathy Guidelines for Genetic Testing, ECG, Imaging, Ambulatory Monitoring and ICD Use HRS – Expert Consensus Statement on Arrhythmogenic Cardiomyopathy Medtronic – FDA Approval of Aurora EV-ICD; 98.7% Successful Defibrillation at Implant Medtronic – Aurora EV-ICD FDA Approval Medtronic – 2026 ENLIGHTEN Real-World Study of Aurora EV-ICD Medtronic – Aurora EV-ICD ENLIGHTEN Results BIOTRONIK – DX Technology: 100,000+ ICD Implantations Across More Than 80 Countries BIOTRONIK – 100,000 DX Devices Implanted BIOTRONIK – FDA Approval of Acticor Sky and Rivacor Sky ICD/CRT-D Systems, April 2026 BIOTRONIK – Acticor Sky and Rivacor Sky FDA Approval Tenaya Therapeutics – FDA RMAT Designation for TN-401 Gene Therapy in PKP2-Associated ARVC, September 2026 Tenaya Therapeutics – TN-401 RMAT Designation Ambry Genetics – ARVCNext Genetic Testing Panel for Inherited ARVC Ambry Genetics – ARVCNext Genetic Test Table of Contents - Global Arrhythmogenic Right Ventricular Dysplasia (ARVD) Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Treatment Type, Drug Class, Diagnostic Method, Device Type, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Treatment Type, Drug Class, Diagnostic Method, Device Type, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Treatment Type, Drug Class, Diagnostic Method, Device Type, and End User Investment Opportunities in the Arrhythmogenic Right Ventricular Dysplasia Market Key Developments and Innovations in ARVD/ARVC Diagnosis and Treatment Mergers, Acquisitions, and Strategic Partnerships in Cardiac Devices and Genetic Diagnostics High-Growth Segments for Investment Opportunities in Genetic Screening, Family-Based Diagnosis, Cardiac MRI, Implantable Cardioverter-Defibrillators, Catheter Ablation, Ambulatory Rhythm Monitoring, and Emerging Gene Therapies Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of ARVD/ARVC Diagnosis, Sudden Cardiac Death Prevention, Genetic Screening, and Long-Term Cardiac Monitoring Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Genetic Screening, Family-Based Diagnosis, and Long-Term Cardiac Surveillance Role of Implantable Cardioverter-Defibrillators, Catheter Ablation, Cardiac MRI, and Ambulatory Rhythm Monitoring in ARVD/ARVC Management Regulatory, Clinical, Genetic, and Access Considerations in Emerging Gene Therapy Development for ARVD/ARVC Global Arrhythmogenic Right Ventricular Dysplasia Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type: Implantable Cardioverter Defibrillators (ICDs) Medication Catheter Ablation Heart Transplantation Market Analysis by Drug Class: Beta-Blockers Antiarrhythmic Drugs ACE Inhibitors and ARBs Diuretics Other Supportive Medications Market Analysis by Diagnostic Method: Electrocardiography (ECG) Cardiac Magnetic Resonance Imaging (MRI) Genetic Testing Echocardiography Holter and Ambulatory ECG Monitoring Electrophysiological Studies Market Analysis by Device Type: Transvenous Implantable Cardioverter Defibrillators Subcutaneous Implantable Cardioverter Defibrillators Cardiac Monitoring Devices Market Analysis by End User: Hospitals Specialty Cardiology Clinics Diagnostic Centers Ambulatory Surgical Centers Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Arrhythmogenic Right Ventricular Dysplasia Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug Class, Diagnostic Method, Device Type, and End User Country-Level Breakdown: United States Canada Mexico Europe Arrhythmogenic Right Ventricular Dysplasia Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug Class, Diagnostic Method, Device Type, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Arrhythmogenic Right Ventricular Dysplasia Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug Class, Diagnostic Method, Device Type, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Arrhythmogenic Right Ventricular Dysplasia Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug Class, Diagnostic Method, Device Type, and End User Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Arrhythmogenic Right Ventricular Dysplasia Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug Class, Diagnostic Method, Device Type, and End User Country-Level Breakdown: GCC Countries South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Medtronic BIOTRONIK Tenaya Therapeutics CENTOGENE Ambry Genetics GeneDx Illumina Blueprint Genetics Labcorp (Invitae) Boston Scientific Corporation Abbott Laboratories Philips Thermo Fisher Scientific Competitive Landscape and Strategic Insights Benchmarking Based on Implantable Defibrillator Technology, Genetic Testing Capabilities, Cardiac Monitoring, Imaging Technology, Electrophysiology Services, and Regional Presence Genetic Diagnostic Capability and Inherited Cardiomyopathy Testing Analysis Implantable Cardioverter-Defibrillator and Cardiac Rhythm Management Positioning Cardiac MRI, ECG, Ambulatory Monitoring, and Electrophysiology Technology Competitiveness Gene Therapy Development and ARVD/ARVC Pipeline Positioning Medtronic Aurora EV-ICD Development and 2023 FDA Approval Positioning BIOTRONIK DX Technology Development and 2024 Clinical Deployment Milestones BIOTRONIK Acticor Sky and Rivacor Sky FDA Approval in 2026 Tenaya Therapeutics TN-401 Development and September 2026 Regenerative Medicine Advanced Therapy Designation Labcorp and Invitae Asset Integration Following the August 2024 Acquisition Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Treatment Type, Drug Class, Diagnostic Method, Device Type, End User, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Cardiac Device and Genetic Diagnostic Vendors Genetic Screening, Diagnostic Testing, and Clinical Monitoring Landscape for ARVD/ARVC Technology Adoption Trends Across Implantable Cardioverter Defibrillators, Cardiac Monitoring Devices, Cardiac MRI, Genetic Testing, Catheter Ablation, and Emerging Gene Therapies List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Treatment Type, Drug Class, Diagnostic Method, Device Type, and End User (2025 vs. 2032) Global Arrhythmogenic Right Ventricular Dysplasia Ecosystem and Value Chain Analysis